Clinical Trial

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Study acronym: CarMob
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2019-04-08; most recent amendment 2026-02-17.
Status change: Suspended → Recruiting 2024-07-18
Status change: Recruiting → Suspended 2024-06-12
Status change: Not Yet Recruiting → Recruiting 2019-06-17
Trial Details
NCT Number NCT03909412
Lead Sponsor Hackensack Meridian Health
Conditions Multiple Myeloma
Enrollment 18 participants
Start Date 2019-10-08
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-18